Detalhe da pesquisa
1.
Empagliflozin after Acute Myocardial Infarction.
N Engl J Med;
390(16): 1455-1466, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38587237
2.
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
N Engl J Med;
2024 May 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38739079
3.
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
Circulation;
2024 Apr 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38581389
4.
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
Circulation;
148(3): 220-228, 2023 07 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37191040
5.
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
Circulation;
148(8): 651-660, 2023 08 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37603600
6.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
N Engl J Med;
385(16): 1451-1461, 2021 10 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34449189
7.
A Novel Circulating MicroRNA for the Detection of Acute Myocarditis.
N Engl J Med;
384(21): 2014-2027, 2021 05 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34042389
8.
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J;
271: 38-47, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38401646
9.
Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events.
J Card Fail;
2024 Apr 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38614444
10.
Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.
Cardiovasc Diabetol;
23(1): 49, 2024 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38302936
11.
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
Curr Cardiol Rep;
26(3): 61-71, 2024 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38551786
12.
Putting More Weight on Obesity Trials in Heart Failure.
Curr Heart Fail Rep;
21(3): 194-202, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38619690
13.
Endpoint adjudication in cardiovascular clinical trials.
Eur Heart J;
44(46): 4835-4846, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37935635
14.
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Circulation;
145(3): 184-193, 2022 01 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34779658
15.
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
Circulation;
146(14): 1046-1055, 2022 10 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36098051
16.
Soluble Urokinase Receptor and Acute Kidney Injury.
N Engl J Med;
382(5): 416-426, 2020 01 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31995687
17.
Clinical outcomes associated with type II myocardial infarction caused by bleeding.
Am Heart J;
263: 85-92, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37201860
18.
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Am Heart J;
256: 25-36, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36372245
19.
A pragmatic clinical trial assessing the effect of a targeted notification and clinical support pathway on the diagnostic evaluation and treatment of individuals with left ventricular hypertrophy (NOTIFY-LVH).
Am Heart J;
265: 40-49, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37454754
20.
Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
J Card Fail;
2023 Oct 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37816446